Related Experiment Video
Updated: Mar 10, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome
Björn Redfors1, Ajay J Kirtane2, Stuart J Pocock3
1Cardiovascular Research Foundation, New York, New York.
Insights
Pre-angiography antithrombotic treatment in non-ST-segment elevation acute coronary syndromes increases bleeding risk and mortality. Early angiography may improve the risk-benefit balance by reducing the need for prolonged upstream antithrombotic therapy.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Upstream antithrombotic drug administration before coronary angiography in non-ST-segment elevation acute coronary syndromes (NSTE-ACS) is common.
- The risks and benefits of this practice are not fully understood.
Purpose of the Study:
- To analyze the incidence of pre-angiography bleeding and ischemic events.
- To assess the association of these events with antithrombotic drugs.
- To evaluate the impact on mortality risk.
Main Methods:
- Analysis of patients from the ACUITY trial undergoing planned angiography.
- Classification of bleeding events using the ACUITY scale (major/nonmajor).
- Kaplan-Meier and Cox proportional hazards analyses were performed.
Main Results:
- 2.0% of patients bled before angiography, with 0.4% experiencing major bleeding.
- Bleeding events increased with time, reaching 10.4% at 96 hours.
- Independent predictors of bleeding included age, renal insufficiency, and multiple antithrombotic drugs.
- Pre-angiography bleeding was linked to longer hospitalization and increased 1-year mortality (8.5% vs. 4.1%).
Conclusions:
- Upstream antithrombotic treatment in NSTE-ACS patients awaiting angiography is associated with increased bleeding and mortality.
- Bleeding avoidance strategies, such as early angiography, may optimize the risk-benefit balance.
- Reducing prolonged upstream antithrombotic therapy could improve patient outcomes.
Background:
Upstream administration of antithrombotic drugs to patients with non-ST-segment elevation acute coronary syndromes before coronary angiography is a common practice despite an incomplete understanding of the risks and benefits.
Objectives:
The authors analyzed the incidence of bleeding and ischemic events occurring before angiography and assessed their association with antithrombotic drugs and mortality risk.
Methods:
All patients from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial with planned angiography after enrollment were included. Bleeding events were classified according to the ACUITY scale as major or nonmajor bleeding. Kaplan-Meier and Cox proportional hazards analyses were performed.
Results:
Of 13,726 patients, 275 (2.0%) bled before angiography, including 52 (0.4%) with major bleeding. Forty-four (0.3%) experienced myocardial infarction. The median time from randomization to coronary angiography was 4.5 h (interquartile ratio [IQR]: 1.7 to 19.7 h) for patients who did not bleed while waiting for angiography and 27.9 h (IQR: 21.9 to 65.6 h) for patients who bled while waiting for angiography (p < 0.001). Bleeding events accrued linearly over time, reaching 10.4% at 96 h post-randomization. Independent predictors of bleeding before angiography included age (adjusted hazard ratio [HR]: 1.03 per year of age; 95% confidence interval [CI]: 1.01 to 1.04; p < 0.001), renal insufficiency (adjusted HR: 1.48; 95% CI: 1.07 to 2.04; p = 0.02), and use of multiple antithrombotic drugs (adjusted HR: 1.33; 95% CI: 1.14 to 1.56; p < 0.001). Bleeding before coronary angiography was associated with longer hospitalization (4.8 days [IQR: 3.0 to 8.9 days] vs. 3.0 days [IQR: 1.9 to 5.9 days]; p < 0.001). Patients who bled before angiography were more likely to die within 1 year than patients who did not bleed (8.5% vs. 4.1%; p < 0.001; adjusted HR: 1.89 (95% CI: 1.23 to 2.90; p = 0.004).
Conclusions:
Upstream antithrombotic treatment of patients with non-ST-segment elevation acute coronary syndromes awaiting coronary angiography is associated with excess bleeding with mortality implications. Bleeding avoidance strategies before angiogram, including early angiography, may negate the need to prolong upstream antithrombotic treatment and improve the overall risk-benefit balance for these patients. (Acute Catheterization and Urgent Intervention Triage Strategy [ACUITY]; NCT00093158).
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview